Amylyx Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Amylyx Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2021 to 2023.
  • Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$72.7M, a 448% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$259M, a 14232% decline year-over-year.
  • Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was $49.3M.
  • Amylyx Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$198M, a 126% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $49.3M +$248M Jan 1, 2023 Dec 31, 2023 10-K 2024-02-22
2022 -$198M -$110M -126% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-22
2021 -$87.9M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.